Table 3.
High-level (group) term | n | EAIR (95% CI) |
Respiratory and mediastinal neoplasms malignant and unspecified | 26 | 0.17 (0.11 to 0.25) |
Breast neoplasms malignant and unspecified (including nipple) | 23 | 0.15 (0.10 to 0.23) |
Gastrointestinal neoplasms malignant and unspecified | 19 | 0.13 (0.08 to 0.20) |
Reproductive neoplasms female malignant and unspecified | 16 | 0.11 (0.06 to 0.17) |
Reproductive neoplasms male malignant and unspecified (all reported cases were prostatic neoplasms) | 10 | 0.07 (0.03 to 0.12) |
Skin neoplasms malignant and unspecified (other than NMSC) | 10 | 0.07 (0.03 to 0.12) |
Renal and urinary tract neoplasms malignant and unspecified | 9 | 0.06 (0.03 to 0.11) |
Lymphomas non-Hodgkin’s B cell | 6 | 0.04 (0.01 to 0.09) |
Endocrine neoplasms malignant and unspecified | 4 | 0.03 (0.01 to 0.07) |
Metastases | 3 | 0.02 (0.00 to 0.06) |
Others* | 15 | 0.10 (0.06 to 0.16) |
*Others are all high-level group terms with 2 cases or fewer, including haematopoietic neoplasms (excluding leukaemias and lymphomas); hepatobiliary neoplasms malignant and unspecified; leukaemias; lymphomas non-Hodgkin’s T cell; lymphomas non-Hodgkin’s unspecified histology; miscellaneous and site unspecified neoplasms malignant and unspecified; neoplasm-related morbidities; nervous system neoplasms malignant and unspecified not elsewhere classified (NEC); not coded; ocular neoplasms; and soft tissue neoplasms malignant and unspecified.
EAIR, exposure-adjusted incidence rate; n, number of subjects in the specified category; NMSC, non-melanoma skin cancer.